1-14 of 14
Enrico De Nigris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Characteristics, Treatment Patterns, and Outcomes of Patients with Mantle Cell Lymphoma By LOT

Helmneh M. Sineshaw, Claire Bai, Enrico De Nigris, Jennifer Prescott, Uzor C. Ogbu, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6279.
https://doi.org/10.1182/blood-2024-194230
Published: 2024
Journal Articles

Clinical Outcomes and Adverse Events Among Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Initiating First-Line (1L) Ibrutinib: Analysis of Subgroups Receiving Subsequent Second Generation (2G) Bruton Tyrosine Kinase Inhibitors, Non-Bruton Tyrosine Kinase Inhibitor Therapy, or Ibrutinib Retreatment in the US Community Oncology Setting

John M. Burke, Ira Zackon, Brittani Wayne, Yunfei Wang, John Murphy, Jennifer Prescott, Shravanthi Gandra, Siyang Leng, Enrico De Nigris
Journal: Blood
Blood (2024) 144 (Supplement 1): 7811.
https://doi.org/10.1182/blood-2024-203667
Published: 2024
Journal Articles

Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

David Dingli, Enrico De Nigris, Siyang Leng, Mohammed Z. H. Farooqui, Halit O. Yapici, Ian Weimer, Weiqi Jiao, Hayden W. Hyatt, Xuan Zhang, Kunal Lodaya, Mavis Obeng-Kusi
Journal: Blood
Blood (2024) 144 (Supplement 1): 3722.
https://doi.org/10.1182/blood-2024-198469
Published: 2024
Journal Articles

Healthcare Resource Utilization and Costs in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Covalent Btki (cBTKi): Real-World Impact of Cardiovascular Adverse Events

Mavis Obeng-Kusi, Enrico De Nigris, Siyang Leng, Mohammed Z. H. Farooqui, Halit O. Yapici, Ian Weimer, Weiqi Jiao, Hayden W. Hyatt, Xuan Zhang, Kunal Lodaya, David Dingli
Journal: Blood
Blood (2024) 144 (Supplement 1): 3738.
https://doi.org/10.1182/blood-2024-200345
Published: 2024
Journal Articles

Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study

Enrico De Nigris, Wendy Y. Cheng, Eric M. Sarpong, Siyang Leng, Mohammed Z.H. Farooqui, Uchechukwu Samuel Agu, Maryaline Catillon, Dominique Lejeune, Nathaniel Downes, Lisa Matay, Mei Sheng Duh, Scott F. Huntington
Journal: Blood
Blood (2023) 142 (Supplement 1): 6523.
https://doi.org/10.1182/blood-2023-178660
Published: 2023
Journal Articles

Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi)

Kevin H. Lin, Lynn Huynh, Xiaoqin Yang, Enrico Zanardo, Lisa Matay, Megan Pinaire, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric M. Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S Davids
Journal: Blood
Blood (2023) 142 (Supplement 1): 4652.
https://doi.org/10.1182/blood-2023-180793
Published: 2023
Journal Articles

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6536.
https://doi.org/10.1182/blood-2023-178727
Published: 2023
Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)

Kevin H. Lin, Lynn Huynh, Xiaoqin Yang, Enrico Zanardo, Lisa Matay, Megan Pinaire, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric M. Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S Davids
Journal: Blood
Blood (2023) 142 (Supplement 1): 1910.
https://doi.org/10.1182/blood-2023-182188
Published: 2023
Journal Articles

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6538.
https://doi.org/10.1182/blood-2023-180060
Published: 2023
Journal Articles

Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status

Enrico De Nigris, Scott F. Huntington, Justin Puckett, Sachin Kamal-Bahl, Mohammed Z.H. Farooqui, Katherine Elizabeth Ryland, Eric Sarpong, Xiaoqin Yang, Jalpa Doshi
Journal: Blood
Blood (2022) 140 (Supplement 1): 5043–5044.
https://doi.org/10.1182/blood-2022-162744
Published: 2022
Journal Articles

Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients

Kevin H. Lin, Lynn Huynh, Xiaoqin Yang, Neema Lema, Lisa Matay, Sobana Balasubramanian, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S. Davids
Journal: Blood
Blood (2022) 140 (Supplement 1): 4150–4152.
https://doi.org/10.1182/blood-2022-160389
Published: 2022
Journal Articles

Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study

Scott F. Huntington, Enrico De Nigris, Justin Puckett, Sachin Kamal-Bahl, Mohammed Z.H. Farooqui, Katherine Elizabeth Ryland, Eric Sarpong, Xiaoqin Yang, Jalpa Doshi
Journal: Blood
Blood (2022) 140 (Supplement 1): 7939–7940.
https://doi.org/10.1182/blood-2022-155903
Published: 2022
Journal Articles

Treatment Patterns of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the Era of Targeted Therapy: A Real-World United States Study

Xiaoqin Yang, Enrico Zanardo, Dominique Lejeune, Enrico De Nigris, Eric Sarpong, Mohammed Z.H. Farooqui, Sidney M. Donzella, François Laliberté
Journal: Blood
Blood (2022) 140 (Supplement 1): 10932–10933.
https://doi.org/10.1182/blood-2022-163702
Published: 2022
Journal Articles

Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib

Xiaoqin Yang, Enrico Zanardo, Dominique Lejeune, Enrico De Nigris, Eric Sarpong, Mohammed Z.H. Farooqui, François Laliberté
Journal: Blood
Blood (2022) 140 (Supplement 1): 10911–10912.
https://doi.org/10.1182/blood-2022-167262
Published: 2022